Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamictal XR adjunctive therapy in primary generalized tonic-clonic seizures
2004-004343-21Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lamotrigine in epilepsy (2 arms), sponsored by GSK. Primary endpoint: Percent change from baseline in PGTC seizure frequency. Started Jan 2005; status: completed.
02
Drugs
lamotrigine
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2004-004343-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004343-21.